About Emisphere
Emisphere is a company based in Roseland (United States) founded in 1986 was acquired by Novo Nordisk in November 2020. The company has 8 employees. Emisphere operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Lyndra and Corcept, among others.
- Headquarter Roseland, United States
- Employees 8
- Stage Public
- SectorsHealthcare
- Website emisphere.com
- Social LinkedIn X
- Acquired by Novo Nordisk (Nov 2020)
- Legal Name Emisphere Technologies, Inc.
- Latest Funding Round$35.17M (USD), Post-IPO
May 2013
- Investors
- Employee Count8
- Acquired byNovo Nordisk
(Nov 2020)
Funding Insights of Emisphere
- Total Rounds 2
- Last Round Post-IPO — $35.17M
- First Round $15M
(Sep 2005)
All 2 funding rounds of Emisphere with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2013 | $35.17M | Post-IPO | – | – | – |
| Sep 2005 | $15M | Debt – Conventional | – | – | – |
1 investors in total: 1 institutional.
Investors in Emisphere
Emisphere has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novo Nordisk.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | 1923 | novonordisk.com | Bagsvaerd, Denmark |
Investor details for Emisphere
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Emisphere
5 dated milestones of Emisphere across 34 years, from founding to its latest funding, stage changes and deals.
- Founded Emisphere is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $15.0M.
- Funding Latest funding round, Post-IPO, of $35.2M.
- Exit Acquired by Novo Nordisk.
Competitors of Emisphere
Emisphere operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Lyndra and Corcept, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| lyndra.com | 2015 | Cambridge, United States | $305.01M | 107 | Innovates long-acting oral therapies to simplify patient medication regimens. | |
| corcept.com | 1998 | Menlo Park, United States | – | 352 | Developer of cortisol modulators for the treatment of various diseases | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| 89bio.com | 2018 | San Francisco, United States | $60M | 70 | Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders | |
| i2obio.com | 2019 | Boston, United States | $53.5M | 6 | Oral drug delivery solutions are provided via liquid technology platform. | |
| genfit.com | 1999 | Loos, France | – | – | Therapeutics for cardiometabolic and neurodegenerative diseases. | |
| ranitherapeutics.com | 2012 | San Jose, United States | $234.14M | – | Technology for oral delivery of large drug molecules is developed. |
Detailed competitors of Emisphere
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Emisphere
Websites that share an audience with Emisphere (emisphere.com).
Websites whose visitors overlap most with Emisphere. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| smblab.be | 100% | – | – | View details | |
| biocydex.net | 100% | – | – | View details | |
macroflux.com | macroflux.com | 100% | – | – | – |
| micrelmed.com | 100% | 2.6K | #6,471,477 | View details | |
activery.com | activery.com | 100% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Emisphere
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Emisphere
Complete news archive for Emisphere
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Emisphere
10 companies that operate in the same segment as Emisphere (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Emisphere
Emisphere was founded in 1986 and raised its 1st funding round 19 years after it was founded.
Emisphere is headquartered in Roseland, United States.
Emisphere has 8 employees.
Emisphere Technologies was founded in 1986 in Roseland, United States, as a specialty pharmaceutical company. Focus is placed on the Eligen technology platform to enable oral formulations of therapeutic agents. Preparation for the U.S. launch of oral Eligen B12, used for dietary management of vitamin B12 deficiency, is underway. Partnerships with global pharmaceutical firms support development of additional oral therapeutics.
Emisphere's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Emisphere has 1 investor. Key investors include Novo Nordisk.
Emisphere operates through Emisphere Technologies, Inc..
Yes. Emisphere was acquired by Novo Nordisk in November 2020.